Our findings provide novel insights into the mechanism by which SGLT2 inhibitors reduce the risk of cancer, particularly prostate cancer, and supports further basic and clinical trials of SGLT2 inhibitors in cancer therapy. This evidence concerns the gene SLC5A2 and prostate carcinoma.